Trial Profile
Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor (nEGFR)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- 31 Jan 2022 Status changed from active, no longer recruiting to discontinued due to COVID-19 related slow enrollment and funding.
- 18 Oct 2021 Planned End Date changed from 1 Nov 2021 to 2 Jul 2022.
- 08 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Nov 2021.